myriamed

What myriamed does

myriamed GmbH is a privately held drug development tools and services company founded in 2012 as a spin-off of the University Medical Center Göttingen, headquartered at Rudolf-Wissell-Straße 28a, 37079 Göttingen, Germany. The company builds proprietary human iPSC-derived cells and macroscale engineered 3D tissue models — branded as the myr-platform (myrCell, myrTissue, myrPlate, myrScreen, myrImager, myrDisease) — that recapitulate healthy and diseased cardiac, skeletal, connective, and neuronal (BENO) tissue in vitro for preclinical drug discovery, target validation, phenotypic screening, dose-finding for first-in-human studies, and toxicity testing. The technical platform is anchored by licensed patent families covering tissue engineering, PSC technology, and screening methods; the integrated myrPlate + myrImager + poleDance workflow delivers non-invasive, high-throughput imaging of up to 48 tissues with micrometer resolution, co-developed with SYNENTEC.

The company monetizes through a dual revenue model: (i) product sales of myrCell lines, myrTissue constructs, and myrPlate consumables via its own Shopify storefront, the ZAGENO life science marketplace, and Science Exchange; and (ii) custom screening and disease-model development services (myrScreen, myrDisease) sold through direct B2B consultation and Science Exchange on a quote basis. Target customers are pharmaceutical and biotech drug developers (primary) and academic / research institutions (secondary), and the company exhibits credentials through conferences (ISSCR, Safety Pharmacology Society, health.tech), the 2022 BMEL Animal Welfare Research Prize, and ecosystem memberships in NetPhaSol, Ksilink, the 4D Bioprinting network, and the ESA Life Science Accelerator (2025). Operationally the company is small (1–10 employees), manages a French joint venture (Myrtil Biotechnologies, with Ksilink, Strasbourg, 2022), and pursues frontier initiatives such as MyrSpaceCardio for microgravity cardiac tissue engineering.

Name

myriamed

Legal name

myriamed GmbH

Website

https://myriamed.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

myriamed provides proprietary human iPSC-derived cells and engineered macroscale 3D tissue models (cardiac, skeletal, fibrotic, neuronal) to pharmaceutical and biotech companies for preclinical drug discovery, phenotypic screening, and disease modeling, complemented by an integrated imaging platform and custom screening services.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Human iPSC-derived cells
• Engineered tissue models
• Drug discovery platforms
• Phenotypic screening services
• Cardiac safety testing

Headquarters

HQ city

Göttingen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Product Sales (myrCell, myrTissue, myrPlate): Sale of proprietary human iPSC-derived cells (cardiomyocytes, skeletal myoblasts, stroma cells), engineered macroscale tissues (cardiac, skeletal, fibrotic, neuronal organoids), and 48-well 3D culture plates. Products ship with Certificate of Analysis. Sold directly via online shop and through distribution partners (ZAGENO, Science Exchange).
2. Screening Services (myrScreen): Customized phenotypic screening services using the company's engineered tissue platforms. Includes primary screens in 48-well format and verification via organ bath measurements. Services adapted to specific customer needs, covering cardiac, skeletal muscle, connective tissue, and neuronal organoid applications.
3. Disease Model Services (myrDisease): Provision of disease-specific tissue models and custom disease model generation upon request, including dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, heart failure, ischemia/reperfusion injury, and drug-induced cardiotoxicity models.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

myriamed sells proprietary human iPSC-derived cells, macroscale engineered 3D tissues (cardiac, skeletal, fibrotic, neuronal organoid), 48-well tissue culture plates, and an automated tissue imaging/analysis system, alongside custom phenotypic screening and disease modeling services. Offerings target pharmaceutical, biotech, and academic research customers for early-stage drug discovery, target validation, safety/efficacy testing, and dose-finding for first-in-human studies.

Product overview

myriamed offers an integrated platform of products and services for drug discovery and development using proprietary human iPSC-derived cells and engineered tissue models. The core portfolio includes myrCell (iPSC-derived cells including cardiomyocytes, skeletal myoblasts, and stroma cells), myrTissue (macroscale engineered tissues including cardiac, skeletal muscle, fibrotic tissue, and neuronal organoids), myrPlate (48-well 3D culture plates with flexible poles), myrImager (automated imaging system co-developed with SYNENTEC), myrScreen (phenotypic screening platform with cardiac, skeletal, connective tissue, and brain variants), and myrDisease (disease models for cardiomyopathy, heart failure, and cardiotoxicity). The platform enables simulation of health and disease in vitro for early drug discovery, target validation, and dose optimization. Services include standardized and custom phenotypic screening solutions.

Differentiator

Problem solved

Functional benefit

Brands

• myrCell: High quality human iPSC-derived cells (cardiomyocytes, skeletal myoblasts, stroma cells) for drug discovery and development.
• myrTissue
• myrPlate
• myrImager
• myrScreen
• myrDisease
• MyrSpaceCardio

Products and services

• myrCell Human iPSC-derived cells (cardiomyocytes, skeletal myoblasts, stroma cells) reprogrammed from human iPSC lines under proprietary serum-free culture conditions, supplied with Certificate of Analysis for use in drug screening, validation, and toxicity testing.
• myrTissue Macroscale human engineered tissues including engineered heart muscle (EHM), skeletal muscle, fibrotic tissue, and bioengineered neuronal organoids (BENOs), shipped at ambient temperature with physiological properties of postnatal tissue and accompanied by Certificate of Analysis.
• myrPlate 48-well 3D cell/tissue culture plates with two flexible poles (stretchers) supporting ring-format tissue growth under defined mechanical load, available in Uniform (same stiffness) and Gradient (soft-to-hard) formats, featuring fluorescent dye for optical tracing of mechanical forces and SBS format compatibility.
• myrImager Automated imaging and analysis platform co-developed with SYNENTEC using pole tracking technology and telecentric optics to non-invasively measure contractile activity of cardiac, skeletal, and connective tissues in 48-well SBS-format myrPlates, with poleDance software extracting contraction/relaxation velocity, amplitude, beating frequency, and rhythm for up to 48 tissues simultaneously.
• myrScreen Two-tiered phenotypic screening platform with a primary screen in the proprietary 48-well format followed by verification using classical organ bath measurements under isometric conditions; endpoints include force, beating rate, rhythm, and contraction kinetics. Includes myrScreen-Cardio, myrScreen-Skeletal, myrScreen-Connective Tissue, and myrScreen-Brain variants.
• myrDisease Disease modeling platform offering models for dilated, hypertrophic, and arrhythmogenic cardiomyopathy, heart failure with reduced and preserved ejection fraction, ischemia/reperfusion injury, and drug-induced cardiotoxicity; custom disease models can be generated upon request.
• myrServices Broad portfolio of standardized services and custom-made solutions for drug development, including phenotypic screening, target validation, lead optimization, and disease modeling using myriamed's cell and tissue platforms.

Quantifiable outcome

• Reduction in clinical attrition rate and acceleration of clinical translation of therapeutic candidates
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• European Space Agency (ESA)coreStrategic or Co-development Partner · 12 December 2025myriamed participates in ESA's Life Science Accelerator with MyrSpaceCardio initiative, advancing cardiac tissue engineering through microgravity benefits. Aims to overcome Earth-bound limitations in engineered heart muscle development and create more physiologically relevant cardiac models for research and drug discovery.
• KIST EuropecoreTechnology or Integration · 12 December 2025KIST Europe is a partner in the MyrSpaceCardio initiative alongside myriamed and Exobiosphere. Contributes spaceflight engineering expertise to the ESA Life Science Accelerator program for advancing cardiac tissue engineering through microgravity.
• ExobiospherecoreTechnology or Integration · 12 December 2025Exobiosphere is a partner in the MyrSpaceCardio initiative alongside myriamed and KIST Europe. Contributes biomedical analytics expertise to the ESA Life Science Accelerator program for advancing cardiac tissue engineering through microgravity.
• SYNENTEC GmbHcoreTechnology or Integration · 2 July 2024myriamed and SYNENTEC co-developed the myrImager, a groundbreaking platform for high-content analysis of pluripotent stem cell-derived heart muscle, skeletal muscle, and connective tissue. SYNENTEC, with 20 years of experience in automated cell imaging microscopes, re-engineered the myrImager to capture specific requirements of pharmaceutical and biotech customers. The myrImager uses pole tracking technology with telecentric optics and poleDance software for automated analysis. The partnership was publicly launched at ISSCR 2024 in Hamburg and first orders were received after the trade fair.
• KsilinkcoreStrategic or Co-development Partner · 6 July 2022Ksilink (French-German public-private association) and myriamed co-founded Myrtil Biotechnologies in Strasbourg, France to develop next-generation therapeutics for dilated cardiomyopathy using iPSC-derived cardiac disease models. The partnership combines myriamed's cardiac disease modeling expertise with Ksilink's high-content screening and AI-driven image analysis capabilities. myriamed is also a member of the Ksilink association, which aims to render drug development faster and more efficient toward precision medicine.
• Myrtil BiotechnologiescoreStrategic or Co-development Partner · 6 July 2022Joint venture between Ksilink and myriamed GmbH, headquartered in Strasbourg, France. Developing next-generation therapeutics to treat dilated cardiomyopathy using patient-specific iPSC-derived cardiomyocyte models expressing TTNtv mutations in 2D and 3D cardiac models. Combines myriamed's cardiac disease modeling with Ksilink's high-content imaging and AI-driven analysis tools.
• International 4D Bioprinting NetworkminorOthers · 28 September 2021myriamed became a member of the ZIM innovation network 4D Bioprinting, led by EurA AG. The network supports innovative products and services in bioprinting for applications in biology, pharmacy, and medicine. Phase 2 of the network runs for 36 months. The network promotes commercialization of innovative technologies through market-oriented R&D projects and establishment of new value chains.
• Science ExchangeminorChannel Partner/ Reseller/ Distributor · 19 March 2021Science Exchange is a SaaS-enabled marketplace platform for outsourced R&D services. myriamed joined as a service provider, enabling customers to inquire about services or request quotes through the platform without additional contracts. Science Exchange provides contracting, project management, and reporting tools for R&D outsourcing.
• Network for Pharma Solutions (NetPhaSol)minorOthers · 6 January 2021NetPhaSol is a cooperation network of more than 50 innovative companies and research institutes focusing on drug discovery and development. myriamed joined as a member to leverage the network for research, development, and marketing of new products, technologies, and services in drug development. The network covers the entire preclinical value chain from target validation to lead optimization.
• ZAGENOminorChannel Partner/ Reseller/ Distributor · 23 November 2020ZAGENO is a life science e-commerce marketplace with approximately 25 million product SKUs from nearly 5,000 brands. myriamed's myrPlates are distributed through ZAGENO, providing visibility to ZAGENO's customer base of research scientists and biotech companies. ZAGENO features its Scientific Score product rating system for unbiased purchasing decisions.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MIMETAS: Provides Organ-on-Chip platforms and disease models for drug development. Comparable as a phenotypic screening and human-relevant disease modeling vendor to pharma/biotech customers.
• Emulate: Commercializes organ-on-chip technology and human-relevant in vitro models for pharmaceutical R&D, competing for the same preclinical safety and efficacy budget as myriamed's myrScreen.
• Ncardia: Specializes in iPSC-derived cardiac and neural cell production and assay services for drug discovery. Directly comparable in target tissue types, customer base, and phenotypic screening services.
• bit.bio: Develops iPSC-derived human cell products at scale using a synthetic biology reprogramming platform. Overlaps with myriamed's myrCell iPSC-derived cardiomyocyte/skeletal myoblast/stroma catalog.
• InSphero: Offers 3D microtissue and organoid models plus screening services for drug discovery and toxicology. Directly comparable in 3D tissue-based phenotypic screening for pharma/biotech.
• Axol Bioscience: Supplies iPSC-derived cells (including cardiomyocytes and neurons) and assembloid/organoid tools for disease modeling. Comparable to myriamed's iPSC-derived cell and neuronal organoid offerings.
• CN Bio: Provides organ-on-chip systems and MPS-based disease models (including cardiac and liver) for drug development, overlapping with myriamed's tissue platform and safety-pharmacology positioning.
• FUJIFILM Cellular Dynamics International: A leading commercial supplier of iPSC-derived cells, including cardiomyocytes, with broad pharma/biotech distribution. Highly comparable to myriamed's myrCell and myrTissue product lines and its drug discovery go-to-market.

Emerging players

• HeartBeat.bio: Focused on 3D cardiac organoid models for drug discovery and cardiotoxicity screening, a direct emerging competitor to myriamed's myrDisease cardiac and cardiotoxicity model franchise.

Broad incumbents

• STEMCELL Technologies: Large life science reagent supplier with iPSC culture, differentiation, and organoid product lines, serving overlapping pharma and academic customers with broader, less specialized catalogs than myriamed.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/myriamed-gmbh
• Xx.com/myriamed_de

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about myriamed